Metastatic breast cancer (mBC) remains an incurable disease, and most patients will experience disease progression during their treatment course. Although endocrine therapy remains the mainstay of ...

Cancer immunotherapy comprises a variety of treatment approaches, incorporating the tremendous specificity of the adaptive immune system (T cells and antibodies) as well as the diverse and potent ...

Surveillance should be guided by presumed risk of recurrence and functional status of the patient (important within the first 2 to 4 years). Medical history, physical examination, and carcinoembryonic ...

Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of ...

Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract ...

Tumor marker testing among Medicare beneficiaries with cancer after changes in insurance coverage for testing. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does ...